Pulmonx

Recent Finacing

Equity

Recent Raise

$83M

Pulmonx develops and commercializes minimally invasive bronchoscopic therapies and diagnostic tools for severe emphysema/COPD, including the Zephyr endobronchial valve, Chartis pulmonary assessment system, and StratX analysis platform.

Founded 1998

California, United States

251-500

Publicly Traded

pulmonx.com

Highlights

Focus Areas

Health Care

Medical Device

Recent Investors

Financials

$223M

Total Raised

6

Funding rounds

18

Investors

Team

Upgrade to view the team

See the team members at Pulmonx.